Literature DB >> 15385919

Tuberculosis transmission in a renal dialysis center--Nevada, 2003.

.   

Abstract

Among persons with chronic renal failure, infection with Mycobacterium tuberculosis is more likely to progress to tuberculosis (TB). Chronic renal failure is an immunocompromising condition associated with cutaneous anergy, which can result in a false-negative tuberculin skin test (TST) result. In 2003, a health-care worker (HCW) (i.e., a hemodialysis technician) in an outpatient renal dialysis center in Nevada became ill with pulmonary TB, exposing more than 400 patients and other employees. The HCW had a previous positive TST result but never received treatment for TB infection. This report summarizes the results of a contact investigation, which suggested that the HCW had transmitted M. tuberculosis to 29 patients and 13 employees. The findings underscore the need for TB screening and treatment of TB infection for all HCWs and patients at high risk.

Entities:  

Mesh:

Year:  2004        PMID: 15385919

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  8 in total

1.  High prevalence of latent tuberculosis infection in dialysis patients using the interferon-gamma release assay and tuberculin skin test.

Authors:  Susan Shin-Jung Lee; Kang-Ju Chou; Horng-Yunn Dou; Tsi-Shu Huang; Yen-Yun Ni; Hua-Chang Fang; Hung-Chin Tsai; Cheng-Len Sy; Jui-Kuang Chen; Kuang-Sheng Wu; Yung-Hsin Wang; Hsi-Hsun Lin; Yao-Shen Chen
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  Risk factors associated with COVID-19 severity among patients on maintenance haemodialysis: a retrospective multicentre cross-sectional study in the UK.

Authors:  Haresh Selvaskandan; Katherine L Hull; Sherna Adenwalla; Safa Ahmed; Maria-Cristina Cusu; Matthew Graham-Brown; Laura Gray; Matt Hall; Rizwan Hamer; Ammar Kanbar; Hemali Kanji; Mark Lambie; Han Sean Lee; Khalid Mahdi; Rupert Major; James F Medcalf; Sushiladevi Natarajan; Boavojuvie Oseya; Stephanie Stringer; Matthew Tabinor; James Burton
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006

3.  Tuberculosis among healthcare workers, United States, 1995-2007.

Authors:  Lauren A Lambert; Robert H Pratt; Lori R Armstrong; Maryam B Haddad
Journal:  Infect Control Hosp Epidemiol       Date:  2012-09-19       Impact factor: 3.254

4.  High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test.

Authors:  S S J Lee; K J Chou; I J Su; Y S Chen; H C Fang; T S Huang; H C Tsai; S R Wann; H H Lin; Y C Liu
Journal:  Infection       Date:  2008-12-10       Impact factor: 3.553

Review 5.  Tuberculosis transmission from healthcare workers to patients and co-workers: a systematic literature review and meta-analysis.

Authors:  Monica Sañé Schepisi; Giovanni Sotgiu; Silvia Contini; Vincenzo Puro; Giuseppe Ippolito; Enrico Girardi
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

6.  Predictive value of the tuberculin skin test and QuantiFERON-tuberculosis Gold In-Tube test for development of active tuberculosis in hemodialysis patients.

Authors:  Ekrem Cengiz Seyhan; Gulşah Gunluoglu; Mehmet Zeki Gunluoglu; Seda Tural; Sinem Sökücü
Journal:  Ann Thorac Med       Date:  2016 Apr-Jun       Impact factor: 2.219

7.  Value of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to M. tuberculosis.

Authors:  Luis Anibarro; Matilde Trigo; Diana Feijoó; Mónica Ríos; Luisa Palomares; Alberto Pena; Marta Núñez; Carlos Villaverde; África González-Fernández
Journal:  BMC Infect Dis       Date:  2012-08-20       Impact factor: 3.090

8.  End-stage Renal Disease and Risk of Active Tuberculosis: a Nationwide Population-Based Cohort Study.

Authors:  Jinsoo Min; Soon Kil Kwon; Hye Won Jeong; Joung-Ho Han; Yeonkook Joseph Kim; Minseok Kang; Gilwon Kang
Journal:  J Korean Med Sci       Date:  2018-12-13       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.